Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2180-188-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-c-dependent manner: Application of Trp2180-188 peptides

Cancer Immunology, Immunotherapy

Volumn 61, Issue 10, 2012, Pages 1671-1682

  Sin, Jeong Im ^a   Park, Jae Bok ^b   Lee, In Hee ^b   Park, Daehan ^b   Choi, Youn Seok ^b   Choe, Jongseon ^a   Celis, Esteban ^c  

^a Kangwon National University   (South Korea)

^b Catholic University of Daegu   (South Korea)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Antitumor immunity; Electroporation; IL 12; Melanoma

Indexed keywords

COMPLEMENTARY DNA; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GRANZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE VACCINE; PERFORIN; RECOMBINANT INTERLEUKIN 12; TRYPTOPHAN RELATED PEPTIDE[180-188] VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ELECTROPORATION; ERADICATION THERAPY; FEMALE; FLOW CYTOMETRY; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTECTION; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T CELL DEPLETION; TREATMENT RESPONSE; TUMOR IMMUNITY;

ANIMALS; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; ELECTROCHEMOTHERAPY; FEMALE; GRANZYMES; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-12; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA, EXPERIMENTAL; MICE; PORE FORMING CYTOTOXIC PROTEINS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84867580255     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1214-8     Document Type: Article

References (35)

1. Lohr F, Lo DY, Zaharoff DA, Hu K, Zhang X, Li Y, Zhao Y, Dewhirst MW, Yuan F, Li CY (2001) Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res 61(8):3281-3284
2. Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D, Hermann SH, Ritz J (1992) Responses of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 175:779-788
3. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G (1989) Identification and purification of natural killer cell stimulator factor (NKSF): a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827-845
4. Germann T, Gately MK, Schoenhaut DS, Lohoff M, Mattner F, Fischer S, Jin SC, Schmitt E, Rude E (1993) Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells. Eur J Immunol 23:1762-1770
5. Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L, Liao F, Farber JM, Pestka S, Trinchieri G, Lee WM (1998) Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9(1):25-34
6. Gately MK, Warrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaughton SE, Anderson TD, Sarmiento U, Hubbard BR, Murphy M (1994) Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 6(1):157-167
7. Lucas ML, Heller L, Coppola D, Heller R (2002) IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 5(6):668-675
8. Li S, Zhang L, Torrero M, Cannon M, Barret R (2005) Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer. Mol Ther 12:942-949
9. Yamashita Y, Shimada M, Hasegawa H, Minagawa R, Rikimaru T, Hamatsu T, Tanaka S, Shirabe K, Miyazaki JI, Sugimachi K (2001) Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 61(3):1005-1012
10. Cemazar M, Jarm T, Sersa G (2010) Cancer electrogene therapy with interleukin-12. Curr Gene Ther 10(4):300-311
11. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26:5896-5903
12. Pavlin D, Cemazar M, Cor A, Sersa G, Pogacnik A (2011) Tozon N (2011) Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiol Oncol 45:31-39
13. Bae SH, Park YJ, Choi YS, Park JB, Kim MS, Sin JI (2007) Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res 13(1):341-349
14. Ye GW, Park JB, Park YJ, Choi YS, Sin JI (2007) Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic antitumor activity. Mol Ther 15(8):1564-1570
15. Sin JI, Kim JM, Bae SH, Lee IH, Park JS, Ryoo HM (2009) Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the Perforin/Granzymemediated Pathway. Mol Ther 17(5):906-913
16. Sin JI, Kim JJ, Arnold RL, Shroff KE, McCallus D, Pachuk C, McElhiney SP, Wolf MW, Pompa-de Bruin SJ, Higgins TJ, Ciccarelli RB, Weiner DB (1999) IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1 type CD4? T cell mediated protective immunity against herpes simplex virus-2 challenge. J Immunol 162:2912-2921
17. Sin JI (2009) Suppression of antitumor protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 cDNA: involvement of nitric oxide in immune suppression. Immunology 128:e707-e717
18. Kim TY, Myoung HJ, Kim JH, Moon IS, Kim TG, Ahn WS, Sin JI (2002) Both E7 and CpG-ODN are required for protective immunity against challenge with human papillomavirus 16 (E6/E7)-immortalized tumor cells: involvement of CD4? and CD8? T cells in protection. Cancer Res 62:7234-7240
19. Corr M, von Damm A, Lee DJ, Tighe H (1999) In vivo priming by DNA injection occurs predominantly by antigen transfer. J Immunol 163:4721-4727
20. Sin JI, Hong SH, Park YJ, Park JB, Choi YS, Kim MS (2006) Antitumor therapeutic effects of E7 subunit and DNA vaccines in an animal cervical cancer model: antitumor efficacy of E7 therapeutic vaccines is dependent on tumor sizes, vaccine doses, and vaccine delivery routes. DNA Cell Biol 25(5):277-286
21. Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968
22. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA (1996) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184:2207-2216
23. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, Yang JC (1997) Identification of tyrosinaserelated protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 185(3):453-459
24. Finkelstein SE, Heimann DM, Klebanoff CA, Antony PA, Gattinoni L, Hinrichs CS, Hwang LN, Palmer DC, Spiess PJ, Surman DR, Wrzesiniski C, Yu Z, Rosenberg SA, Restifo NP (2004) Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J Leukoc Biol 76(2):333-337
25. Guevara-Patino JA, Engelhorn ME, Turk MJ, Liu C, Duan F, Rizzuto G, Cohen AD, Merghoub T, Wolchok JD, Houghton AN (2006) Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest 116(5):1382-1390
26. Amos S, Pegram HJ, Westwood JA, John LB, Devaud C, Clarke CJ, Restifo NP, Smyth MJ, Darcy PK, Kershaw MH (2011) Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother 60(5):671-683
27. Cho H, Lee YR, Celis E (2011) Interferon gamma limits the effectiveness of melanoma peptide vaccines. Blood 117(1): 135-144
28. Kishida T, Asada H, Satoh E, Tanaka S, Shinya M, Hirai H, Iwai M, Tahara H, Imanishi J, Mazda O (2001) In vivo electroporation- mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther 8(16):1234-1240
29. Tamura T, Nishi T, Goto T, Takeshima H, Dev SB, Ushio Y, Sakata T (2001) Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer. Hum Gene Ther 12(10):1265-1276
30. Shibata M, Ito Y, Morimoto J, Kusakabe K, Yoshinaka R, Otsuki Y (2006) In vivo electrogene transfer of interleukin-12 inhibits tumor growth and lymph node and lung metastases in mouse mammary carcinomas. J Gene Med 8(3):335-352
31. Pavlin D, Cemazar M, Kamensek U, Tozon N, Pogacnik A, Sersa G (2009) Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma. Cancer Biol Ther 8(22):2114-2122
32. Heller L, Cruz YL, Ferraro B, Yang H, Heller R (2010) Plasmid injection and application of electric pulses alter endogenous mRNA and protein expression in B16.F10 mouse melanomas. Cancer Gene Ther 17(12):864-871
33. Ferraro B, Heller LC, Cruz YL, Guo S, Donate A, Heller R (2011) Evaluation of delivery conditions for cutaneous plasmid electrotransfer using a multielectrode array. Gene Ther 18(5):496-500
34. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N (2000) Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191(3):423-434
35. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL (1997) Effects of single-dose interleukin-12 exposure on interleukin- 12-Associated toxicity and interferon-gamma production. Blood 90:2541-2548